soft tissue sarcoma

Showing 5 posts of 5 posts found.


Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

April 26, 2019
Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …


Eli Lilly gains accelerated approval from FDA for soft tissue sarcoma drug

October 20, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, US, soft tissue sarcoma

Eli Lilly received the positive news that their drug, Lartruvo, has been granted accelerated approval for use in conjunction with …


EU recommendation for Lilly’s soft tissue cancer drug

September 19, 2016
Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma

The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with …


Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016
Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …

NICE approves Trabectedin

January 19, 2010
Sales and Marketing NICE, PharmaMar, Trabectedin, soft tissue sarcoma

Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval. …

Latest content